In a recent interview with BioSpectrum Asia, Caidya CEO Barbara Lopez Kunz discusses the growing importance of the Asia-Pacific (APAC) region in global clinical development and the opportunities it presents for sponsors.
Barbara shares insights into China’s evolving regulatory landscape, accelerated IND review pathways, and the operational considerations involved in integrating APAC markets into global clinical development programmes.
She also highlights a key principle for successful development in the region: combining local expertise with globally consistent execution.
The interview further explores the strategic approach to supporting Asian biotech companies expanding into international markets, as well as helping global sponsors incorporate APAC into their clinical development strategies.